Although the oral treatment seems to work, an analysis of the results from 12 clinical trials finds kids who got an immunotherapy have a greater rate of serious reactions.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

One person with multiple myeloma and one with sarcoma are the first so far to receive the genetically engineered T cells in the study.

At least a handful of patients have developed active TB after receiving cancer treatment designed to boost the immune system’s antitumor response.

The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines.

Researchers describe ways to study how cancer cells evade therapies that harness the immune system.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.